aluates Reports

$ 0.0

Automative

Global Neuroendocrine Carcinoma Treatment Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-9R5991

Global Neuroendocrine Carcinoma Treatment Market Insights Forecast to 2028

BUY CHAPTERS

Global Neuroendocrine Carcinoma Treatment Market Research Report 2025

Code: QYRE-Auto-9R5991

Report

June 2025

Pages:71

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Pfizer Inc

Novartis

Chiasma Inc

Ipsen S A

AbbVie

Bausch Health

Jubilant

Mateon

Teva Pharmaceutical Industries Ltd

Roche

Neuroendocrine Carcinoma Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Neuroendocrine Carcinoma Treatment Market

The global market for Neuroendocrine Carcinoma Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Carcinoma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Carcinoma Treatment.

The Neuroendocrine Carcinoma Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuroendocrine Carcinoma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neuroendocrine Carcinoma Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neuroendocrine Carcinoma Treatment Market Report

Report Metric	Details
Report Name	Neuroendocrine Carcinoma Treatment Market
CAGR	5%
Segment by Type	Somatostatin Analogs Targeted Therapy Chemotherapy
Segment by Application	Hospitals Clinics Oncology Centers Ambulatory Surgical Centers Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Novartis, Chiasma, Inc., Ipsen, AbbVie, Bausch Health, Jubilant, Teva Pharmaceutical Industries Ltd., Roche, Mateon
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroendocrine Carcinoma Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neuroendocrine Carcinoma Treatment Market report?

Ans: The main players in the Neuroendocrine Carcinoma Treatment Market are Pfizer, Novartis, Chiasma, Inc., Ipsen, AbbVie, Bausch Health, Jubilant, Teva Pharmaceutical Industries Ltd., Roche, Mateon

What are the Application segmentation covered in the Neuroendocrine Carcinoma Treatment Market report?

Ans: The Applications covered in the Neuroendocrine Carcinoma Treatment Market report are Hospitals, Clinics, Oncology Centers, Ambulatory Surgical Centers, Others

What are the Type segmentation covered in the Neuroendocrine Carcinoma Treatment Market report?

Ans: The Types covered in the Neuroendocrine Carcinoma Treatment Market report are Somatostatin Analogs, Targeted Therapy, Chemotherapy

Recommended Reports

Cancer Drug Therapies

Cancer Diagnostics Devices

Targeted and Novel Therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Somatostatin Analogs

1.2.3 Targeted Therapy

1.2.4 Chemotherapy

1.3 Market by Application

1.3.1 Global Neuroendocrine Carcinoma Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Oncology Centers

1.3.5 Ambulatory Surgical Centers

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neuroendocrine Carcinoma Treatment Market Perspective (2020-2031)

2.2 Global Neuroendocrine Carcinoma Treatment Growth Trends by Region

2.2.1 Global Neuroendocrine Carcinoma Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Neuroendocrine Carcinoma Treatment Historic Market Size by Region (2020-2025)

2.2.3 Neuroendocrine Carcinoma Treatment Forecasted Market Size by Region (2026-2031)

2.3 Neuroendocrine Carcinoma Treatment Market Dynamics

2.3.1 Neuroendocrine Carcinoma Treatment Industry Trends

2.3.2 Neuroendocrine Carcinoma Treatment Market Drivers

2.3.3 Neuroendocrine Carcinoma Treatment Market Challenges

2.3.4 Neuroendocrine Carcinoma Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neuroendocrine Carcinoma Treatment Players by Revenue

3.1.1 Global Top Neuroendocrine Carcinoma Treatment Players by Revenue (2020-2025)

3.1.2 Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Neuroendocrine Carcinoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Neuroendocrine Carcinoma Treatment Revenue

3.4 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio

3.4.1 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Treatment Revenue in 2024

3.5 Global Key Players of Neuroendocrine Carcinoma Treatment Head office and Area Served

3.6 Global Key Players of Neuroendocrine Carcinoma Treatment, Product and Application

3.7 Global Key Players of Neuroendocrine Carcinoma Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Neuroendocrine Carcinoma Treatment Breakdown Data by Type

4.1 Global Neuroendocrine Carcinoma Treatment Historic Market Size by Type (2020-2025)

4.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Type (2026-2031)

5 Neuroendocrine Carcinoma Treatment Breakdown Data by Application

5.1 Global Neuroendocrine Carcinoma Treatment Historic Market Size by Application (2020-2025)

5.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Neuroendocrine Carcinoma Treatment Market Size (2020-2031)

6.2 North America Neuroendocrine Carcinoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Neuroendocrine Carcinoma Treatment Market Size by Country (2020-2025)

6.4 North America Neuroendocrine Carcinoma Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neuroendocrine Carcinoma Treatment Market Size (2020-2031)

7.2 Europe Neuroendocrine Carcinoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2020-2025)

7.4 Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size (2020-2031)

8.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neuroendocrine Carcinoma Treatment Market Size (2020-2031)

9.2 Latin America Neuroendocrine Carcinoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2020-2025)

9.4 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size (2020-2031)

10.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Neuroendocrine Carcinoma Treatment Introduction

11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.1.5 Pfizer Recent Development

11.2 Novartis

11.2.1 Novartis Company Details

11.2.2 Novartis Business Overview

11.2.3 Novartis Neuroendocrine Carcinoma Treatment Introduction

11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.2.5 Novartis Recent Development

11.3 Chiasma, Inc.

11.3.1 Chiasma, Inc. Company Details

11.3.2 Chiasma, Inc. Business Overview

11.3.3 Chiasma, Inc. Neuroendocrine Carcinoma Treatment Introduction

11.3.4 Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.3.5 Chiasma, Inc. Recent Development

11.4 Ipsen

11.4.1 Ipsen Company Details

11.4.2 Ipsen Business Overview

11.4.3 Ipsen Neuroendocrine Carcinoma Treatment Introduction

11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.4.5 Ipsen Recent Development

11.5 AbbVie

11.5.1 AbbVie Company Details

11.5.2 AbbVie Business Overview

11.5.3 AbbVie Neuroendocrine Carcinoma Treatment Introduction

11.5.4 AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.5.5 AbbVie Recent Development

11.6 Bausch Health

11.6.1 Bausch Health Company Details

11.6.2 Bausch Health Business Overview

11.6.3 Bausch Health Neuroendocrine Carcinoma Treatment Introduction

11.6.4 Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.6.5 Bausch Health Recent Development

11.7 Jubilant

11.7.1 Jubilant Company Details

11.7.2 Jubilant Business Overview

11.7.3 Jubilant Neuroendocrine Carcinoma Treatment Introduction

11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.7.5 Jubilant Recent Development

11.8 Teva Pharmaceutical Industries Ltd.

11.8.1 Teva Pharmaceutical Industries Ltd. Company Details

11.8.2 Teva Pharmaceutical Industries Ltd. Business Overview

11.8.3 Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Introduction

11.8.4 Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.8.5 Teva Pharmaceutical Industries Ltd. Recent Development

11.9 Roche

11.9.1 Roche Company Details

11.9.2 Roche Business Overview

11.9.3 Roche Neuroendocrine Carcinoma Treatment Introduction

11.9.4 Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.9.5 Roche Recent Development

11.10 Mateon

11.10.1 Mateon Company Details

11.10.2 Mateon Business Overview

11.10.3 Mateon Neuroendocrine Carcinoma Treatment Introduction

11.10.4 Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025)

11.10.5 Mateon Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Pfizer Inc

Novartis

Chiasma Inc

Ipsen S A

AbbVie

Bausch Health

Jubilant

Mateon

Teva Pharmaceutical Industries Ltd

Roche

List of Tables

Table 1. Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Somatostatin Analogs

Table 3. Key Players of Targeted Therapy

Table 4. Key Players of Chemotherapy

Table 5. Global Neuroendocrine Carcinoma Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Neuroendocrine Carcinoma Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Neuroendocrine Carcinoma Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Neuroendocrine Carcinoma Treatment Market Share by Region (2020-2025)

Table 9. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Neuroendocrine Carcinoma Treatment Market Share by Region (2026-2031)

Table 11. Neuroendocrine Carcinoma Treatment Market Trends

Table 12. Neuroendocrine Carcinoma Treatment Market Drivers

Table 13. Neuroendocrine Carcinoma Treatment Market Challenges

Table 14. Neuroendocrine Carcinoma Treatment Market Restraints

Table 15. Global Neuroendocrine Carcinoma Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Neuroendocrine Carcinoma Treatment Market Share by Players (2020-2025)

Table 17. Global Top Neuroendocrine Carcinoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2024)

Table 18. Ranking of Global Top Neuroendocrine Carcinoma Treatment Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Neuroendocrine Carcinoma Treatment, Headquarters and Area Served

Table 21. Global Key Players of Neuroendocrine Carcinoma Treatment, Product and Application

Table 22. Global Key Players of Neuroendocrine Carcinoma Treatment, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Neuroendocrine Carcinoma Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2020-2025)

Table 26. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2026-2031)

Table 28. Global Neuroendocrine Carcinoma Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Application (2020-2025)

Table 30. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Application (2026-2031)

Table 32. North America Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Neuroendocrine Carcinoma Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Neuroendocrine Carcinoma Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 47. Pfizer Company Details

Table 48. Pfizer Business Overview

Table 49. Pfizer Neuroendocrine Carcinoma Treatment Product

Table 50. Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 51. Pfizer Recent Development

Table 52. Novartis Company Details

Table 53. Novartis Business Overview

Table 54. Novartis Neuroendocrine Carcinoma Treatment Product

Table 55. Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 56. Novartis Recent Development

Table 57. Chiasma, Inc. Company Details

Table 58. Chiasma, Inc. Business Overview

Table 59. Chiasma, Inc. Neuroendocrine Carcinoma Treatment Product

Table 60. Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 61. Chiasma, Inc. Recent Development

Table 62. Ipsen Company Details

Table 63. Ipsen Business Overview

Table 64. Ipsen Neuroendocrine Carcinoma Treatment Product

Table 65. Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 66. Ipsen Recent Development

Table 67. AbbVie Company Details

Table 68. AbbVie Business Overview

Table 69. AbbVie Neuroendocrine Carcinoma Treatment Product

Table 70. AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 71. AbbVie Recent Development

Table 72. Bausch Health Company Details

Table 73. Bausch Health Business Overview

Table 74. Bausch Health Neuroendocrine Carcinoma Treatment Product

Table 75. Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 76. Bausch Health Recent Development

Table 77. Jubilant Company Details

Table 78. Jubilant Business Overview

Table 79. Jubilant Neuroendocrine Carcinoma Treatment Product

Table 80. Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 81. Jubilant Recent Development

Table 82. Teva Pharmaceutical Industries Ltd. Company Details

Table 83. Teva Pharmaceutical Industries Ltd. Business Overview

Table 84. Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Product

Table 85. Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 86. Teva Pharmaceutical Industries Ltd. Recent Development

Table 87. Roche Company Details

Table 88. Roche Business Overview

Table 89. Roche Neuroendocrine Carcinoma Treatment Product

Table 90. Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 91. Roche Recent Development

Table 92. Mateon Company Details

Table 93. Mateon Business Overview

Table 94. Mateon Neuroendocrine Carcinoma Treatment Product

Table 95. Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2020-2025) & (US$ Million)

Table 96. Mateon Recent Development

Table 97. Research Programs/Design for This Report

Table 98. Key Data Information from Secondary Sources

Table 99. Key Data Information from Primary Sources

Table 100. Authors List of This Report

List of Figures

Figure 1. Neuroendocrine Carcinoma Treatment Picture

Figure 2. Global Neuroendocrine Carcinoma Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Neuroendocrine Carcinoma Treatment Market Share by Type: 2024 VS 2031

Figure 4. Somatostatin Analogs Features

Figure 5. Targeted Therapy Features

Figure 6. Chemotherapy Features

Figure 7. Global Neuroendocrine Carcinoma Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Neuroendocrine Carcinoma Treatment Market Share by Application: 2024 VS 2031

Figure 9. Hospitals Case Studies

Figure 10. Clinics Case Studies

Figure 11. Oncology Centers Case Studies

Figure 12. Ambulatory Surgical Centers Case Studies

Figure 13. Others Case Studies

Figure 14. Neuroendocrine Carcinoma Treatment Report Years Considered

Figure 15. Global Neuroendocrine Carcinoma Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Neuroendocrine Carcinoma Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Neuroendocrine Carcinoma Treatment Market Share by Region: 2024 VS 2031

Figure 18. Global Neuroendocrine Carcinoma Treatment Market Share by Players in 2024

Figure 19. Global Top Neuroendocrine Carcinoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Treatment Revenue in 2024

Figure 21. North America Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Neuroendocrine Carcinoma Treatment Market Share by Country (2020-2031)

Figure 23. United States Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Neuroendocrine Carcinoma Treatment Market Share by Country (2020-2031)

Figure 27. Germany Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Share by Region (2020-2031)

Figure 35. China Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Neuroendocrine Carcinoma Treatment Market Share by Country (2020-2031)

Figure 43. Mexico Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Share by Country (2020-2031)

Figure 47. Turkey Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 51. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 52. Chiasma, Inc. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 53. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 54. AbbVie Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 55. Bausch Health Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 56. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 57. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 58. Roche Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 59. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Neuroendocrine Tumor NET Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Neuroendocrine Tumor Drug Market Research Report 2024

Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Brain Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Nasopharyngeal Carcinoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Small Cell Lung Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Rare Endocrine Disorders Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Next Generation Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drugs for Non Small Cell Lung Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

NDDS Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pancreatic Endocrine Tumor Drug Market Research Report 2025

Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lung Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drugs for Head and Neck Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Endocrine Therapy Drugs for Breast Cancer Market Research Report 2024

Global Neurologic Disorder Treatment Drug Market Research Report 2024

Novel Drug Delivery Systems for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Breast Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Neurodegenerative Disease Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions